Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

CRPS-RISE Outcomes Registry

15 listopada 2026 zaktualizowane przez: Ambros Therapeutics, Inc.

A Prospective Longitudinal Outcomes Registry of Complex Regional Pain Syndrome Type 1 (CRPS-1) in Participants Treated With Neridronate in the CRPS-RISE Trial and/or Open-Label Extension (OLE)

The goal of this observational study is to learn about how well neridronate keeps working in the months after treatment. For 12 or up to 24 months while the registry is open participants will answer online survey questions about their CRPS pain, medication use or procedures done and how CRPS affects what they are able to do.

Przegląd badań

Status

Rekrutacyjny

Warunki

Szczegółowy opis

The primary objective of the registry is to evaluate the long-term effectiveness of IV neridronate across three outcome domains in participants who qualified in CRPS-RISE with early, warm CRPS-1 and a positive triple phase bone scan, following prior treatment with four infusions of neridronate 100 mg IV over approximately a 10-day period. The three outcome domains include, patient report of health status, CRPS-1 related clinical events, and disability status.

No neridronate treatment will be given as part of the registry and limited safety information will be collected. Participants will have received neridronate either through CRPS-RISE and/or through the Open Label Extension.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

270

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • North Carolina
      • Durham, North Carolina, Stany Zjednoczone, 27703
        • Rekrutacyjny
        • CRPS-RISERegistry
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

The registry target population for provisional enrollment includes all participants in CRPS-RISE, the parent trial of the Registry. After the completion of the last participant's last visit in CRPS-RISE and the unblinding of the trial, the Enrolled Study Cohort will be participants confirmed to have completed a four-infusion course of neridronate. The Enrolled Study Cohort will also include participants in the Open Label Extension study.

Opis

Inclusion Criteria:

  • Participants from CRPS-RISE

    1. Completion of four infusions of IP (neridronate 100 mg over a ~ 10-day period [or the renally modified dosing, as applicable] or placebo) in CRPS-RISE .

    2. Completed CRPS-RISE with a final trial visit at Week 6 (Visit 8) or later.

      Participants who meet both criteria will be provisionally enrolled pending post-trial unblinding and be included in the Provisionally Enrolled Study Cohort.

      After CRPS-RISE last patient last visit unblinding, only participants who meet the following neridronate exposure criterion #3 will continue in registry follow-up and be included in the Enrolled Study Cohort:

    3. Completion of 4-infusions of neridronate 100 mg over approximately a 10-day period in CRPS-RISE.

  • Participants from the Open Label Extension (OLE)

    1. Completion of 4 infusions of neridronate 100 mg over approximately a 10-day period (or the renally modified dosing, as applicable) in the OLE.
    2. Completed OLE with a final trial visit at Week 6 (Visit 8) or later.

Exclusion Criteria:

There are no exclusion criteria.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: CASE_ONLY
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Provisionally Enrolled Study Cohort

Participants provisionally enrolled in the registry. (Note: Participants provisionally enrolled who do not meet this neridronate-exposure criterion will not continue registry follow-up.)

Enrolled Study Cohort

Participants who have consented to participate and meet all inclusion criteria including confirmation of completing four infusions of neridronate.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change from baseline to each registry assessment of average pain in the past 24 hours.
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

Average pain (24-hour recall) reported on an 11-point numeric rating scale. This is recorded every 90 days from entry.

Every 3 months from enrollment until up to 2 years after entry.
Time to loss of benefit where benefit is 50% reduction in average pain intensity from baseline to Week 12 of the CRPS-RISE trial.
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

Each patient reported registry assessment of average pain in the past 24 hours will use an 11 point numeric rating scale. The analysis will be limited to participants who experienced benefit. Data will be summarized as Kaplan-Meier estimates.

Every 3 months from enrollment until up to 2 years after entry.
Change from baseline to each registry assessment in CRPS Severity Score Self-Report (CSS-SR) total score and individual items.
Ramy czasowe: Every 3 months from entry to up to 24 months of participation.

The CSS-SR is designed as a patient self-report questionnaire to assess the severity of CRPS signs and symptoms using plain language to assess 13 concepts.

Every 3 months from entry to up to 24 months of participation.
Change from baseline to each registry assessment in Patient Global Impression of Severity (PGI-S).
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

The 6-point PGI-S is an overall assessment of the participant's perception of the severity of their CRPS condition at the time of the assessment. Participants will respond to the question "How would you rate the symptoms of your CPRS at this time." Possible responses are scored from 0 to 5 representing none, minimal, mild, moderate, severe, very severe.

Every 3 months from enrollment until up to 2 years after entry.
Change from baseline to each registry assessment in each of the Short Form 12 Health Survey (SF-12, Acute Version 2) domains, Physical Component Score (PCS), Mental Component Score (MCS), and individual items.
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

The SF-12 is a widely used measure of general health status used in observational studies across a broad range of disease areas. It is a shortened version of the SF-36 V2.0 and yields 8 domain scores and a Physical Component Summary and Mental Component Summary. Each domain score is calculated by transforming raw responses to a 0-100 scale, where higher scores indicate better health status.

Every 3 months from enrollment until up to 2 years after entry.
Change from baseline to each registry assessment in Daily Sleep Interference Scale (DSIS) in the past 24 hours on an 11-point numeric rating scale.
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

The DSIS is a single-item scale that assesses "how much did your pain interfere with your sleep during the past 24 hours?" (0 = did not interfere; 10 = completely interfered

Every 3 months from enrollment until up to 2 years after entry.
CRPS-1 Related Clinical Events during the 3 months preceding each registry assessment.
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

The CRPS-1 Treatment Checklist was developed for this registry to assess commonly used pharmacologic treatments (e.g., opioids, neuropathic pain agents, ketamine, NSAIDs, bisphosphonates, corticosteroids, and topicals),interventional procedures (e.g., spinal cord or dorsal root ganglion stimulation, peripheral nerve stimulation, stellate/lumbar sympathetic blocks, sympathetic ablation/sympathectomy, intrathecal pump implant, and Bier block), and non-invasive rehabilitation therapies (e.g., physical therapy, occupational therapy, mirror visual feedback, psychological therapies, scrambler therapies or acupuncture). Participants select all CRPS-related treatments used in the past 3 months. The checklist will also record participation in the open-label clinical trial and is intended for descriptive evaluation of long-term CRPS-1 treatments with a focus on resource intensive events. The outcome domain assesses the long-term effectiveness of neridronate through patient reports.

Every 3 months from enrollment until up to 2 years after entry.
Disability Status
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

During the 3 months preceding each registry assessment the participant reported applying for or being on short-term disability, long-term disability, or workers compensation. As a binary endpoint, it will be summarized as frequencies and percentages. The domain assesses the long-term effectiveness of neridronate through patient reports of short-term disability, long-term disability, and workers compensation.

Every 3 months from enrollment until up to 2 years after entry.

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Healthcare Use and Costs (Provisional)
Ramy czasowe: Every 3 months from enrollment until up to 2 years after entry.

The potential for inclusion of linked health care claims and electronic health record data will be enabled by having participants consent to tokenizing their identifying information.

Every 3 months from enrollment until up to 2 years after entry.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Joel Castellanos, MD, UCSD

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

17 października 2026

Zakończenie podstawowe (Szacowany)

16 kwietnia 2029

Ukończenie studiów (Szacowany)

16 kwietnia 2029

Daty rejestracji na studia

Pierwszy przesłany

31 sierpnia 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

3 września 2026

Pierwszy wysłany (Rzeczywisty)

10 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 listopada 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • AMBTX-01-R01

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .